MED II, managed by ArchiMed SAS signed a letter of intent to acquire DIESSE Diagnostica Senese S.p.A. from Orphée SA (WSE:ORP) and founders on September 28, 2018. ArchiMed SAS will carry out the due diligence examination process, as a result of which decisions regarding the conclusion or non-conclusion of transaction will be made and transaction document will be prepared. The letter of intent will end six-week period from the start of the due diligence process. If, after this period, ArchiMed SAS confirms the terms of the transaction as agreed in the letter of intent, the exclusivity will be extended until January 15, 2019. Pier Francesco Faggiano, Alessandro Fosco Fagotto, Ludovica Balbo di Vinadio, Tommaso Zanirato, Elena Venturini, Andrea Fiorelli and Matteo Chinaglia of Dentons acted as legal advisors, Marco Bastasin, Luca Bosco and Ivana Azzollini of Deloitte acted as accountants, Klaus Nestler and Alexander Bücker-Flürenbrock of ACXIT Capital Partners acted as M&A advisors, Alberto Arrotta and Fabio Minervini of Essentia Advisory acted as financial advisors to ArchiMed SAS. Alessandro Giovannelli, Stefano Traniello and Giulia Contestabile of Giovannelli e Associati acted as legal advisors to Orphée SA. Franco Barucci and Andrea Palatini of Gatti Pavesi Bianchi acted as legal advisors and Giancarlo Maestrini, Marco Rognoni and Massimo Polidori of Azimut Global Counseling acted as financial advisors to the founders of DIESSE Diagnostica Senese S.p.A. Marina Balzano and Giulio Asquini of Orrick acted as legal advisors to MPS Capital Services and BPER.